These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8413856)

  • 1. Failure of intravenous pentagastrin challenge to induce panic-like effects in rhesus monkeys.
    Rupniak NM; Schaffer L; Siegl P; Iversen SD
    Neuropeptides; 1993 Aug; 25(2):115-9. PubMed ID: 8413856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses.
    Abelson JL; Nesse RM
    Biol Psychiatry; 1994 Jul; 36(2):73-83. PubMed ID: 7948449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients.
    van Megen HJ; Westenberg HG; den Boer JA; Haigh JR; Traub M
    Psychopharmacology (Berl); 1994 Apr; 114(3):449-55. PubMed ID: 7855203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of time of preparation on pentagastrin-induced symptom, endocrine and cardiovascular responses.
    Khan S; Briggs H; Abelson JL
    Psychiatry Res; 2008 Mar; 158(2):141-6. PubMed ID: 18222546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCK4-induced panic in healthy subjects I: psychological and cardiovascular effects.
    Jerabek I; Boulenger JP; Bradwejn J; Lavallée YJ; Jolicoeur FB
    Eur Neuropsychopharmacol; 1999 Jan; 9(1-2):149-55. PubMed ID: 10082241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptides and anxiety: a dose-response evaluation of pentagastrin in healthy volunteers.
    McCann UD; Slate SO; Geraci M; Uhde TW
    Anxiety; 1994-1995; 1(6):258-67. PubMed ID: 9160584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder.
    Bradwejn J; Koszycki D; Annable L; Couëtoux du Tertre A; Reines S; Karkanias C
    Biol Psychiatry; 1992 Nov; 32(10):903-12. PubMed ID: 1467375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associated endocrine, physiological and behavioral changes in rhesus monkeys after intravenous corticotropin-releasing factor administration.
    Kalin NH; Shelton SE; Kraemer GW; McKinney WT
    Peptides; 1983; 4(2):211-5. PubMed ID: 6312433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentagastrin has panic-inducing properties in obsessive compulsive disorder.
    de Leeuw AS; Den Boer JA; Slaap BR; Westenberg HG
    Psychopharmacology (Berl); 1996 Aug; 126(4):339-44. PubMed ID: 8878350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of medroxyprogesterone pretreatment on pentagastrin-induced panic symptoms in females with panic disorder.
    Le Mellédo J; Jhangri GS; Lott P; Tait GR; McManus K; Geddes M; Chrapko W; Lara N
    Psychiatry Res; 2001 Apr; 101(3):237-42. PubMed ID: 11311926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pentagastrin-induced sleep panic attacks: panic in the absence of elevated baseline arousal.
    Geraci M; Anderson TS; Slate-Cothren S; Post RM; McCann UD
    Biol Psychiatry; 2002 Dec; 52(12):1183-9. PubMed ID: 12488064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholecystokinin and anxiety in normal volunteers: an investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype B antagonist L-365,260.
    Lines C; Challenor J; Traub M
    Br J Clin Pharmacol; 1995 Mar; 39(3):235-42. PubMed ID: 7619662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyrotropin-releasing hormone: a potential comparator for the panicogenic effects of pentagastrin and CCK?
    Coupland N; Malizia A; Bailey J; Nutt D
    Biol Psychiatry; 1996 Mar; 39(6):465-6. PubMed ID: 8679797
    [No Abstract]   [Full Text] [Related]  

  • 14. A comparison of the effects of intravenous pentagastrin on patients with social phobia, panic disorder and healthy controls.
    McCann UD; Slate SO; Geraci M; Roscow-Terrill D; Uhde TW
    Neuropsychopharmacology; 1997 Mar; 16(3):229-37. PubMed ID: 9138439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corticotropin-releasing factor administered intraventricularly to rhesus monkeys.
    Kalin NH; Shelton SE; Kraemer GW; McKinney WT
    Peptides; 1983; 4(2):217-20. PubMed ID: 6312434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular and respiratory responses to a panicogenic agent in anaesthetised female Wistar rats at different stages of the oestrous cycle.
    Brack KE; Jeffery SM; Lovick TA
    Eur J Neurosci; 2006 Jun; 23(12):3309-18. PubMed ID: 16820020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of pentagastrin-induced pressor response in conscious rats by the CCK-B receptor antagonist CI-988 and chlordiazepoxide.
    Webb JK; Rupniak NM; Boyce S
    Regul Pept; 1996 Jan; 61(1):71-6. PubMed ID: 8701030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ethinyl estradiol on the panic response to the panicogenic agent pentagastrin.
    McManus K; Tait GR; Bellavance F; Le Mellédo JM
    J Affect Disord; 2001 Oct; 66(2-3):273-9. PubMed ID: 11578682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of prolonged ketamine exposure on cardiovascular physiology in pregnant and infant rhesus monkeys (Macaca mulatta).
    Hotchkiss CE; Wang C; Slikker W
    J Am Assoc Lab Anim Sci; 2007 Nov; 46(6):21-8. PubMed ID: 17994669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of propranolol on symptom and endocrine responses to pentagastrin.
    Khan S; Liberzon I; Abelson JL
    Psychoneuroendocrinology; 2004 Oct; 29(9):1163-71. PubMed ID: 15219640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.